Prevencio Receives FDA Breakthrough Device Designation for HART CADhs, Its Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease

KIRKLAND, Wash.--(BUSINESS WIRE)-- Prevencio, Inc., the leader in artificial intelligence-powered blood tests for cardiovascular diagnostics, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its HART CADhs® test. This designation recognizes HART CADhs as an innovative technology for identifying obstructive coronary artery disease (CAD) —a condition responsible for significant morbidity and mortality. The designation is reserved for technologies that offer significant advantages over existing solutions and address unmet medical needs.
HART CADhs is the only AI-based multi-protein blood test capable of accurately detecting blockage in the heart's arteries. By combining multiple cardiac proteins with proprietary machine learning algorithms, HART CADhs delivers actionable insight through a simple, non-invasive blood draw, bridging critical diagnostic gaps in current cardiovascular care.
'The FDA's Breakthrough Device Designation is a pivotal milestone in our mission to revolutionize the diagnosis and treatment of obstructive coronary artery disease,' said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. 'We are committed to expanding the use of HART CADhs from outpatient settings into emergency care environments to ensure that patients receive earlier, more accurate, and potentially life-saving diagnoses.'
HART CADhs is currently available as a Lab Developed Test (LDT) with a 2 to 10-day turnaround, making it ideal for evaluating stable, non-urgent patients. The Breakthrough Device Designation enables close collaboration with the FDA and an expedited review process, supporting Prevencio's goal to advance the test into a rapid, FDA-cleared in vitro diagnostic (IVD) with a one-hour result time —ideal for evaluating chest pain patients in emergency rooms.
HART CADhs was developed using Prevencio's proprietary HART platform in collaboration with researchers at Massachusetts General Hospital (MGH). In clinical research, the test demonstrated high accuracy (0.86 AUC) in detecting obstructive CAD, significantly outperforming standard-of-care tests such as stress echocardiography and nuclear imaging, which yielded only 0.52 AUC.
'With nearly half of U.S. counties lacking access to a cardiologist and long wait times in urban centers, a simple, accurate blood test to diagnose obstructive CAD offers tremendous potential to improve access to early diagnosis and intervention,' said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Chief Scientific Officer at the Baim Institute for Clinical Research and Principal Investigator for the HART test development and validation. 'Our studies show HART CADhs is informative in a broad range of patient types including those with acute symptoms as well as those not diagnosed with a heart attack yet may have dangerous arterial obstruction. This suggests usefulness in both acute and outpatient settings.'
Cardiovascular disease remains the leading cause of death in the United States and worldwide. According to the American Heart Association, cardiovascular disease and stroke account for over $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio's HART blood tests are designed to improve patient outcomes and reduce costs through earlier, more accurate, and more accessible diagnostics.
In addition to HART CADhs, Prevencio also offers HART CVE®, a second AI-driven, multi-protein blood test that assesses a patient's one-year risk of heart attack, stroke, or cardiovascular death. Both tests are currently available to healthcare providers.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing cardiac diagnostics with AI-driven blood tests for cardiovascular disease and custom diagnostics for diagnostic, medical device and pharmaceutical companies. Using this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
HART test results have been peer-reviewed published 35 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; and Transcatheter Cardiovascular Therapeutics Sessions) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Biomarkers in Medicine; Journal of American Heart Association; and European Journal of Preventive Cardiology).
About Prevencio, Inc.
Prevencio's vision is to revolutionize cardiac diagnostics with AI-driven blood tests—thereby improving care with highly accessible, accurate and cost-effective diagnosis and earlier treatment. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The company does not undertake to update disclosures contained in this press release.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

4 hours ago

• Yahoo

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@

Time Business News

9 hours ago

• Time Business News

Prozenith Reviews 2025: The Pink Salt Trick That's Melting Fat Fast!

Official Website: Click Here What is ProZenith? ProZenith is a natural dietary supplement formulated to support effective weight management and overall well-being. It is designed for individuals seeking to enhance their metabolism, increase energy levels, and support fat burning without the use of harsh chemicals or stimulants. By promoting the body's natural ability to burn fat and boost energy, ProZenith helps users achieve and maintain a healthier lifestyle. The supplement is manufactured in FDA-registered and GMP-certified facilities, ensuring its quality and safety. It also supports better mental clarity, digestive health, and immune function. With consistent use and alongside a balanced diet and exercise, ProZenith becomes a reliable ally for anyone on a weight loss or wellness journey. Its plant-based formula makes it a suitable option for those who prefer natural health solutions. Users often report improvements not only in physical performance but also in mood, focus, and daily motivation. The Science Behind ProZenith ProZenith operates on the scientific principle of metabolic enhancement. It helps the body enter a state where fat is used as the primary source of fuel rather than carbohydrates, a process similar to ketosis. This metabolic shift increases energy efficiency and encourages fat loss. Additionally, it supports hormonal balance and appetite regulation, helping reduce unnecessary cravings. This supplement promotes better nutrient absorption and reduces bloating, which further supports the weight loss process. By combining natural compounds known for their holistic benefits, ProZenith addresses various aspects of health to provide a science-backed, safe path to sustainable weight management. Ingredients of ProZenith The ingredients in ProZenith are carefully selected natural compounds known for supporting weight management, energy production, and overall wellness. Each component plays a unique role in promoting metabolism, enhancing fat burning, reducing inflammation, and supporting hormonal balance. Pumpkin Seed Pumpkin seed is renowned for its high antioxidant content and essential fatty acids, which work synergistically to support prostate and urinary health. These nutrients help regulate hormonal balance, reduce inflammation, and protect against oxidative stress. Regular consumption can lead to improved bladder control and decreased discomfort, enhancing daily comfort and urinary function. Lycopene Lycopene is a potent antioxidant primarily found in tomatoes, celebrated for its ability to neutralize harmful free radicals and prevent cellular damage. This compound contributes significantly to immune system support and reduces inflammation throughout the body. Its protective effects extend to promoting heart health and maintaining a healthy prostate, making it a vital nutrient for overall wellness. Broccoli Broccoli is a nutrient-dense vegetable rich in sulforaphane, a natural compound with powerful detoxifying and anti-inflammatory properties. Sulforaphane helps protect cells from damage, supports the body's detoxification pathways, and enhances immune defenses. Additionally, broccoli supports digestive health by improving gut function and reducing inflammation in the digestive tract. Beta Sitosterol Beta Sitosterol is a plant-derived sterol known for its ability to improve urinary flow and support prostate health. It helps maintain balanced cholesterol levels and promotes hormonal equilibrium, which is essential for men experiencing symptoms of an enlarged prostate. Beyond urinary benefits, Beta Sitosterol also supports cardiovascular health and overall well-being. Pygeum Africanum Bark Extracted from the African cherry tree, Pygeum Africanum Bark has a long history in traditional medicine for supporting urinary tract and prostate health. It helps reduce inflammation, ease discomfort during urination, and lessen the frequency of nighttime bathroom visits. Its anti-inflammatory and soothing properties contribute to improved urinary flow and enhanced quality of life. Benefits Accelerated Fat Burning: Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Appetite Control: Naturally reduces cravings and supports better portion control to help avoid overeating. Naturally reduces cravings and supports better portion control to help avoid overeating. Increased Energy Levels: Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Enhanced Mental Clarity: Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Improved Digestive Health: Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Immune System Support: Strengthens your body's natural defenses to keep you healthier while managing weight. Pros Natural formula Supports weight loss Boosts energy Enhances focus Improves mood Reduces cravings Promotes fat burning Aids digestion Non-GMO and stimulant-free Backed by a money-back guarantee Cons Only available online Not suitable for children Results may vary Requires consistent use How To Use? Take two ProZenith capsules daily with a glass of water, preferably before meals. For best results, follow a consistent routine and support it with a healthy diet and regular physical activity. This helps maximize the supplement's benefits and promotes long-term well-being. Any Side Effects? ProZenith has no side effects when taken as directed, thanks to its natural, non-GMO, plant-based ingredients. Users commonly report increased energy levels and enhanced metabolism without any discomfort or adverse reactions. Its gentle and carefully crafted formula is designed for daily use and is well-tolerated by most individuals. This makes ProZenith a safe and reliable option for those looking to support their health and weight management naturally, without the worry of unwanted side effects or harsh stimulants. Money Back Guarantee ProZenith comes with a 60-day money-back guarantee, giving you the confidence to try it risk-free. If within 60 days you feel the supplement doesn't meet your expectations or you're not satisfied with the results, you can easily request a full refund by contacting customer support. This generous refund policy ensures you have ample time to evaluate the product's effectiveness without any financial worry. With this guarantee, ProZenith offers a worry-free opportunity to invest in your health and well-being, making it a trustworthy choice for those seeking natural support. Pricing & Availability Basic Pack (2 Bottles): $158 + $9.99 Shipping Most Popular (3 Bottles): $207 with Free Shipping Best Value (6 Bottles): $294 with Free Shipping and the biggest savings Where to Buy? ProZenith can be purchased exclusively through its official website. This ensures you're getting the authentic product, complete with quality assurance, secure checkout, and eligibility for bonuses and money-back guarantees. Avoid third-party platforms that may sell counterfeit versions. Buying directly also gives you access to customer support and the latest promotional offers. For your safety and best experience, always purchase from the verified source. Conclusion As an expert, I strongly recommend ProZenith for anyone seeking a natural and effective solution to support weight management and overall wellness. This supplement uses powerful plant-based ingredients that work together to boost metabolism, increase energy, and promote fat burning without harsh chemicals or stimulants. It also enhances mental clarity and supports digestive health, making it ideal for daily use. With regular use, ProZenith helps achieve sustainable results while strengthening the immune system. Supported by positive customer reviews and a 60-day money-back guarantee, it offers a risk-free way to improve your health. If you want a reliable, natural boost to your wellness journey, ProZenith is definitely worth trying. >> (LIMITED SUPPLIES) Click Here to Buy ProstaVive for The Lowest Price Online << TIME BUSINESS NEWS

Yahoo

10 hours ago

• Yahoo

Children's cough medicine recalled, may cause food poisoning: FDA

(WJW) – A nationwide recall of a popular children's cough medicine has been announced due to a microbial contamination, which the U.S. Food and Drug Administration warns could cause two types of foodborne illnesses. According to the recall alert, Medtech Products Inc., a Prestige Consumer Healthcare Inc. company, is voluntarily recalling five lots of Little Remedies Honey Cough Syrup due to the presence of Bacillus cereus and loss of shelf-stability. Ready-to-eat meals sold at Walmart and Kroger recalled after multiple deaths The Cleveland Clinic describes Bacillus cereus as a microscopic organism that can cause food poisoning. 'One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food,' states the recall alert. 'Diarrhea may be a small volume or profuse and watery. Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.' Browns rookie QB cited for speeding over 100 mph According to the FDA, the affected lots were distributed nationwide through retailers and online from Dec. 14, 2022, through June 4, 2025. Here's what to look for: Item UPC Lot # Exp. Date 7-56184-10737-9 0039 11/2025 0545 01/2026 0640 02/2026 0450 05/2026 1198 12/2026 'All lots of Little Remedies® Honey Cough 4 FL OZ (118 mL) still within expiry are being included in the scope of the recall,' reports the FDA. 'This recall does not include any other Little Remedies® products.' Consumers who have the recalled product are advised to stop using it 'immediately' and should contact their physician or healthcare provider if they experience any problems that may be related to the product. The FDA states that the company will offer reimbursement for consumers who have purchased products from the recalled lots. CLICK HERE to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.